Cargando…
Quality of Life in Hormone Receptor–Positive HER-2(+) Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib
BACKGROUND. A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients. The primary endpoint of progression-free survival (PFS) in patients whose tumors were human epiderma...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228031/ https://www.ncbi.nlm.nih.gov/pubmed/20798196 http://dx.doi.org/10.1634/theoncologist.2010-0012 |